The Tenaquip Foundation donation will allow for faster drug development, better care for ALS patients

 

A generous donation by The Tenaquip Foundation will improve the quality of care available to ALS patients at The Neuro, and increase the rate at which researchers can evaluate new ALS drugs.

Classified as: ALS, amyotrophic lateral sclerosis, Reed Family, Tenaquip Foundation, clinical trial unit, drug development, Angela Genge, Guy Rouleau
Published on: 3 Jul 2017

Montreal, Quebec and Vancouver, British Columbia – Working together to accelerate research into neurological diseases, three leading players in Canada’s health sciences sector are joining forces in a unique multi-million dollar partnership to create a novel drug development platform that will help advance new therapeutics for some of the most debilitating conditions such as amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and Parkinson’s disease.

Classified as: drug development, Merck, CDRD, Parkinson's, Guy Rouleau
Published on: 16 Mar 2017
Back to top